Our industry-leading portfolio and pipeline include three core mechanisms to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.